Loading the security page…
The series is stated in the current share scale after splits; dividends are not included in the price
Ionis switches off the synthesis of individual proteins with short molecules — the platform an entire field grew out of.
The company spent decades developing antisense drugs when almost nobody believed in them, and carried the technology through to approved medicines. The principle is the same as RNA interference: not to block a finished protein but to stop the cell from making it.
For a long time the company lived on licensing: it advanced a programme to a certain stage and handed it to large pharmaceutical partners for royalties. It is now launching drugs itself, which promises a larger share of success and demands a sales force of its own. Risks: trial outcomes, the cost of launching alone and competition from related technologies. The company pays no dividend.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Ionis Pharmaceuticals, Inc. (IONS) is a company in the Health care sector; its shares trade on Nasdaq.
The price of Ionis Pharmaceuticals, Inc. (IONS) on November 2, 2026 is 41.74 $, −4.09 % on the day. Over the past year the price changed by −40.17 %. Market capitalization is 7.19 billion $, rank 34 among 380 stocks of the same industry with a known capitalization.
Ionis Pharmaceuticals, Inc. trades on Nasdaq under the ticker IONS. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks IONS has traded between 42.08 $ and 86.74 $. As of 2 November 2026 the price stood 1.39 % of the way from the 52-week low to the high.
Over one year IONS shares fell 40.17 %; over six months they fell 44.42 %. Volatility over 90 days is 62.19 %. Dividends are not included: this is price change only, as of 2 November 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 8.2, above the sector median of 3.6. Price to book is 16.4, above the sector median of 2.5. Calculated from reports for the period ending 30 June 2026.
Ionis Pharmaceuticals, Inc. reported revenue of 874M $ and a net loss of 565M $ over the last four quarters. Net margin is −64.66 %. Revenue changed by −7.41 % year over year. Earnings per share are −3.46 $. Market capitalisation is 7.2B $.
IONS has a return on equity of −128.53 %, below the sector median of −40.58 %. Return on assets is −18.87 %, above the sector median of −30.08 %. Operating margin is −68.00 %, below the sector median of −20.96 %.